lep-f1
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 2, 2017 (NCT03302897)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mycobacterium lepraeImmunity, active
Mycobacterium leprae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03947437 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Immune Design, Oswaldo Cruz Foundation |
| NCT03302897 | Phase 1 | Oct 2, 2017 | American Leprosy Missions, Immune Design |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Design | For profit | 2 | 2 | 2 | 2017 |
| American Leprosy Missions | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Oswaldo Cruz Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1